Quantum Cyber N.V. Completes $6M Private Placement, Undergoes Change of Control and Board Overhaul
QUCY sits 74% above its 52-week low of $0.4 on elevated volume (6.0× avg).
Summary
Quantum Cyber N.V. (formerly Mainz Biomed N.V.) completed a $6 million private placement with David E. Lazar, leading to a change of control, a new board, and a massive increase in authorized shares, addressing going concern issues at the cost of extreme shareholder dilution.
Key Events · Financing and Capital Events · QUCY
-
$6 Million Private Placement Completed
The company finalized a $6 million private placement of convertible preferred shares with David E. Lazar, with the second tranche closing on April 22, 2026, providing critical capital.
-
Change of Control
David E. Lazar became the controlling shareholder, holding over 95% of the company's voting rights on a fully-diluted basis as a result of the financing.
-
Extreme Dilution Authorized
The preferred shares are convertible into up to 477 million ordinary shares, representing a substantial increase over current outstanding shares and enabling significant future dilution for existing shareholders.
-
Corporate Rebranding and Governance Overhaul
The company changed its name from Mainz Biomed N.V. to Quantum Cyber N.V., saw the resignation of four directors and its Co-CEO, and appointed two new directors, significantly restructuring its board and management.
Analysis · QUCY · Life Sciences
This 8-K details a comprehensive corporate transformation for Quantum Cyber N.V., formerly Mainz Biomed N.V. The completion of a $6 million private placement with David E. Lazar, while providing critical capital to a company previously facing "going concern" doubts, comes at an extremely high cost to existing shareholders due to the massive potential dilution. David Lazar's acquisition of over 95% of voting rights signifies a complete change of control, which is further reflected in the significant overhaul of the board of directors and the resignation of the Co-CEO. The company's rebranding and the dramatic increase in authorized shares underscore a new strategic direction and the potential for further substantial equity issuance. Investors should recognize this as a recapitalization that effectively transfers control and a large portion of equity value to the new investor, fundamentally altering the investment thesis.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 40.7% of the 388 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.42%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QUCY was trading at $0.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3M. The 52-week trading range was $0.40 to $4.43. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.